कृपया अन्य खोज का प्रयास करें
Advanced Accelerator Applications SA develops, produces, and commercializes molecular nuclear, diagnostic, and therapeutic medicine products. It offers oxodotreotides; dotatate injections; edotreotide solutions; flurochol; and gluscan for oncology, cardiology, and neurology. It also provides LysaKare, a solution for reduction of kidney radiation exposure during peptide-receptor radionuclide therapy; DOPAVIEW, an aromatic amino acid that accumulates rapidly in target tissues; CARDIOGEN, closed system used to produce rubidium chloride for intravenous use; NEUROLITE, a radiopharmaceutical preparation of technetium bicisate injection; LUMARK, a radiopharmaceutical precursor; and LEUKOKIT, a medical device for the separation and labelling of autologous leukocytes. Additionally, it offers theragnostic platform, which is based on radiolabeling a targeting molecule for a receptor expressed on a tumor cell that helps in diagnosis, monitoring, and staging. The company was incorporated in 2002 and is based in Saint-Genis-Pouilly, France. Advanced Accelerator Applications SA operates as a subsidiary of Novartis AG.
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है